Advertisement

Langenbeck's Archives of Surgery

, Volume 396, Issue 8, pp 1145–1156 | Cite as

The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant

  • Irvin M. ModlinEmail author
  • Steven F. Moss
  • Bjorn I. Gustafsson
  • Ben Lawrence
  • Simon Schimmack
  • Mark Kidd
Review Article

Abstract

Background

Neuroendocrine neoplasms (NENs) are increasing in incidence and prevalence. This reflects greater clinical awareness, effective imaging, and increasing pathological diagnostic recognition. Although the identification and treatment of clinical neuroendocrine syndromes are established, there is confusion when a NEN has no discernible clinical symptoms.

Discussion

Nonfunctional tumors are usually diagnosed incidentally and at a later stage largely because either they do not secrete a bioactive product or do so, but in a form that is either inactive or in quantities that have no discernible effect. Nevertheless, the histopathology is indistinguishable from functional NENs, and tumors exhibit somatostatin receptor expression, and positive immunohistochemistry for neuroendocrine cell markers (CgA, NSE/synaptophysin). Similarly, their rates of growth and metastatic behavior are, like other NENs, predictably based on staging and grading (mitotic rate and Ki67 expression). Both types are diagnosed biochemically (CgA) and by imaging in an identical fashion with computed tomography, magnetic resonance imaging, somatostatin receptor scintigraphy, and endoscopic ultrasound. NENs, irrespective of function or bioactive secretory profile, respond with equal efficacy to the same regimen of surgery or antitumor drugs (e.g., somatostatin analogs with or without tyrosine kinase inhibitors/antiangiogenics or cytotoxics) depending on grade. Given the efficacy of somatostatin analogs in increasing progression free survival, nonfunctional NENs should be managed identically to symptomatic NENs. The consideration of NENs as functional or nonfunctional is an archaic clinical concept that should be discarded since the tumors are indistinguishable at a cellular, biological, and morphological level. All current evidences indicate that their diagnosis and treatment should follow the same common principles.

Keywords

Carcinoid Functional Epidemiology Incidence Nonfunctional Pancreatic neuroendocrine tumor SEER Survival 

Notes

Acknowledgments

MK was supported in part by NIH: DK080871. BL was supported in part by a grant from the Genesis Oncology Trust, Auckland, New Zealand.

Conflicts of interest

None.

References

  1. 1.
    Modlin IM, Oberg K, Chung DC et al (2008) The current status of gastroenteropancreatic neuroendocrine tumors. Lancet Oncol 9:61–72PubMedCrossRefGoogle Scholar
  2. 2.
    Yao JC, Hassan M, Phan A (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072PubMedCrossRefGoogle Scholar
  3. 3.
    Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E (2008) Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 100(18):1282–1289PubMedCrossRefGoogle Scholar
  4. 4.
    Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin I (2011) The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbeck's Archives 396(3):273–298CrossRefGoogle Scholar
  5. 5.
    Kent RB 3rd, van Heerden JA, Weiland LH (1981) Nonfunctioning islet cell tumors. Ann Surg 193(2):185–190PubMedCrossRefGoogle Scholar
  6. 6.
    Nomura N, Fujii T, Kanazumi N et al (2009) Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg 16(5):639–647PubMedCrossRefGoogle Scholar
  7. 7.
    Lawrence B, Gustafsson B, Chan A, Svejda B, Kidd M, Modlin I (2010) The epidemiology of gastroenteropancreatic tumors. Endocrinol Metab Clin North Am 40(1):1–18CrossRefGoogle Scholar
  8. 8.
    Franko J, Feng W, Yip L, Genovese E, Moser AJ (2010) Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg 14(3):541–548PubMedCrossRefGoogle Scholar
  9. 9.
    Chung TP, Hunt SR (2006) Carcinoid and neuroendocrine tumors of the colon and rectum. Clin Colon Rectal Surg 19(2):45–48PubMedCrossRefGoogle Scholar
  10. 10.
    Onaitis MW, Kirshbom PM, Hayward TZ et al (2000) Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 232(4):549–556PubMedCrossRefGoogle Scholar
  11. 11.
    Soreide O, Berstad T, Bakka A et al (1992) Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 111(1):48–54PubMedGoogle Scholar
  12. 12.
    Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U (2004) Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann NY Acad Sci 1014:222–233PubMedCrossRefGoogle Scholar
  13. 13.
    Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14(23):7798–7803PubMedCrossRefGoogle Scholar
  14. 14.
    Zerbi A, Falconi M, Rindi G et al (2010) Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 105(6):1421–1429PubMedCrossRefGoogle Scholar
  15. 15.
    Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med 79(1):101–107PubMedGoogle Scholar
  16. 16.
    Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M (2010) Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17(9):2427–2443PubMedCrossRefGoogle Scholar
  17. 17.
    Oberndorfer S. Karzinoide tumores des Dunndarms. Frankf Z Pathol. 1907:426–443Google Scholar
  18. 18.
    DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours, pathology and genetics of tumours of endocrine organs. IARC, LyonGoogle Scholar
  19. 19.
    Plockinger U, Rindi G, Arnold R et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80(6):394–424PubMedCrossRefGoogle Scholar
  20. 20.
    Bosman F, Carneiro F, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system. WHO/IARC, LyonGoogle Scholar
  21. 21.
    Klimstra DS, Modlin IM, Adsay NV et al (2010) Pathologic reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathologic data set. Am J Surg Pathol 34(3):300–313PubMedCrossRefGoogle Scholar
  22. 22.
    Metz DC (1999) Diagnosis of non-Zollinger-Ellison syndrome, non-carcinoid syndrome, enteropancreatic neuroendocrine tumours. Ital J Gastroenterol Hepatol 31(Suppl 2):S153–S159PubMedGoogle Scholar
  23. 23.
    Oberg K, Skogseid B (1998) The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1. J Intern Med 243(6):471–476PubMedCrossRefGoogle Scholar
  24. 24.
    Stivanello M, Berruti A, Torta M (2001) Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 12(Suppl 2):S73–S77PubMedCrossRefGoogle Scholar
  25. 25.
    Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19(5):753–781PubMedCrossRefGoogle Scholar
  26. 26.
    Jensen RT, Niederle B, Mitry E et al (2006) Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84(3):173–182PubMedCrossRefGoogle Scholar
  27. 27.
    Zhao J, Moch H, Scheidweiler AF et al (2001) Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosom Cancer 32(4):364–372PubMedCrossRefGoogle Scholar
  28. 28.
    Forget MA, Turcotte S, Beauseigle D (2007) The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 96(4):646–653PubMedCrossRefGoogle Scholar
  29. 29.
    Gonzalez-Sancho JM, Aguilera O, Garcia JM et al (2005) The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 24(6):1098–1103PubMedCrossRefGoogle Scholar
  30. 30.
    Johansson TA, Westin G, Skogseid B (2009) Identification of Achaete-scute complex-like 1 (ASCL1) target genes and evaluation of DKK1 and TPH1 expression in pancreatic endocrine tumours. BMC Cancer 9:321PubMedCrossRefGoogle Scholar
  31. 31.
    Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199–203PubMedCrossRefGoogle Scholar
  32. 32.
    Floridia G, Grilli G, Salvatore M et al (2005) Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors. Cancer Genet Cytogenet 156(1):23–30PubMedCrossRefGoogle Scholar
  33. 33.
    Rigaud G, Missiaglia E, Moore PS et al (2001) High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 61(1):285–292PubMedGoogle Scholar
  34. 34.
    Woodard PK, Feldman JM, Paine SS, Baker ME (1995) Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr 19(3):400–405PubMedCrossRefGoogle Scholar
  35. 35.
    Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25(3):458–511PubMedCrossRefGoogle Scholar
  36. 36.
    Garbrecht N, Anlauf M, Schmitt A et al (2008) Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 15(1):229–241PubMedCrossRefGoogle Scholar
  37. 37.
    Rinke A, Muller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663PubMedCrossRefGoogle Scholar
  38. 38.
    Ganti AK, West WW, Lackner RP, Kessinger A (2010) Current concepts in the diagnosis and management of small-cell lung cancer. Oncology (Williston Park) 24(11):1034–1039Google Scholar
  39. 39.
    Stridsberg M, Oberg K, Li Q et al (1995) Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144:49–59PubMedCrossRefGoogle Scholar
  40. 40.
    Rorstad O (2005) Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 89:151–160PubMedCrossRefGoogle Scholar
  41. 41.
    Stridsberg M, Eriksson B, Oberg K, Janson ET (2003) A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 177(2):337–341PubMedCrossRefGoogle Scholar
  42. 42.
    Panzuto F, Severi C, Cannizzaro R et al (2004) Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Investig 27(1):6–11Google Scholar
  43. 43.
    Nikou GC, Marinou K, Thomakos P et al (2008) Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 8(4–5):510–519PubMedCrossRefGoogle Scholar
  44. 44.
    Wu TJ, Lin CL, Taylor RL, Kvols LK, Kao PC (1997) Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. Mayo Clin Proc 72(12):1111–1115PubMedCrossRefGoogle Scholar
  45. 45.
    Corbetta S, Peracchi M, Cappiello V et al (2003) Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. J Clin Endocrinol Metab 88(7):3117–3120PubMedCrossRefGoogle Scholar
  46. 46.
    Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD (2005) Current status of gastrointestinal carcinoids. Gastroenterology 128(6):1717–1751PubMedCrossRefGoogle Scholar
  47. 47.
    Murugesan SV, Varro A, Pritchard DM (2009) Review article: strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 29(10):1055–1068PubMedCrossRefGoogle Scholar
  48. 48.
    Marko J, Lamba R, Miller F, Buchman A, Spies S, Nikolaidis P (2008) OctreoScan positive Crohn's disease mimicking an ileal carcinoid tumor. J Clin Gastroenterol 42(1):66–68PubMedCrossRefGoogle Scholar
  49. 49.
    Hofmann M, Maecke H, Borner R et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28(12):1751–1757PubMedCrossRefGoogle Scholar
  50. 50.
    Papotti M, Bongiovanni M, Volante M et al (2002) Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440(5):461–475PubMedCrossRefGoogle Scholar
  51. 51.
    Missiaglia E, Dalai I, Barbi S et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28(2):245–255PubMedCrossRefGoogle Scholar
  52. 52.
    Kimura N, Pilichowska M, Date F, Kimura I, Schindler M (1999) Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 5(11):3483–3487PubMedGoogle Scholar
  53. 53.
    Kulaksiz H, Eissele R, Rossler D et al (2002) Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50(1):52–60PubMedCrossRefGoogle Scholar
  54. 54.
    Fjallskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET (2003) Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 20(1):59–67PubMedCrossRefGoogle Scholar
  55. 55.
    Corleto VD, Falconi M, Panzuto F et al (2009) Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology 89(2):223–230PubMedCrossRefGoogle Scholar
  56. 56.
    Pais SA, Al-Haddad M, Mehdi M et al (2010) EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc 71(7):1185–1193PubMedCrossRefGoogle Scholar
  57. 57.
    Norton JA, Fraker DL, Alexander HR et al (2006) Surgery increases survival in patients with gastrinoma. Ann Surg 244(3):410–419PubMedGoogle Scholar
  58. 58.
    Chamberlain RS, Canes D, Brown KT et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445PubMedCrossRefGoogle Scholar
  59. 59.
    O'Toole D, Ruszniewski P (2005) Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 19(4):585–594PubMedCrossRefGoogle Scholar
  60. 60.
    O'Toole D, Maire F, Ruszniewski P (2003) Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 10(4):463–468PubMedCrossRefGoogle Scholar
  61. 61.
    van Vilsteren FG, Baskin-Bey ES, Nagorney DM et al (2006) Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl 12(3):448–456PubMedCrossRefGoogle Scholar
  62. 62.
    Modlin I, Pavel M, Kidd M, Gustafsson B (2010) Somatostatin analogues: an appraisal of their utility and efficacy. Aliment Pharmacol Ther 31(2):169–188PubMedGoogle Scholar
  63. 63.
    Kulke MH, Hornick JL, Frauenhoffer C et al (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15(1):338–345PubMedCrossRefGoogle Scholar
  64. 64.
    Janson ET, Sorbye H, Welin S et al (2010) Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 49(6):740–756PubMedCrossRefGoogle Scholar
  65. 65.
    Kulke MH (2007) Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am 21(3):433–455, vii-viiiPubMedCrossRefGoogle Scholar
  66. 66.
    Moertel CG, Kvols LK, O'Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68(2):227–232PubMedCrossRefGoogle Scholar
  67. 67.
    Modlin IM, Kidd M, Drozdov I, Siddique ZL, Gustafsson BI (2008) Pharmacotherapy of neuroendocrine cancers. Expert Opin Pharmacother 9(15):2617–2626PubMedCrossRefGoogle Scholar
  68. 68.
    Pavel M, Hainsworth JD, Baudin E, et al. (2010) A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide lar vs placebo + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol 21(Suppl 8):Abst LBA8Google Scholar
  69. 69.
    Yao JC, Shah MH, Ito T, et al. (2010) A randomized, double-blind, placebo-controlled, multicenter phase iii trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). Ann Oncol 21(Suppl 8):Abst LBA9Google Scholar
  70. 70.
    Kulke M, Blaszkowsky L, Zhu A, Flortio S, Regan E (2010 ) Phase I/II study of everolimus (RAD001) in combination with Temozolamide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). Proc Am Soc Clin Oncol Gast Int:Abstr 223Google Scholar
  71. 71.
    Kulke MH, Stuart K, Enzinger PC et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406PubMedCrossRefGoogle Scholar
  72. 72.
    van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ (2009) Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 5(7):382–393PubMedCrossRefGoogle Scholar
  73. 73.
    Scarpa A, Mantovani W, Capelli P et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6):824–833PubMedCrossRefGoogle Scholar
  74. 74.
    Pape UF, Jann H, Muller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113(2):256–265PubMedCrossRefGoogle Scholar
  75. 75.
    Pomianowska E, Gladhaug IP, Grzyb K et al (2010) Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems. Scand J Gastroenterol 45(7–8):971–979PubMedCrossRefGoogle Scholar
  76. 76.
    Panzuto F, Nasoni S, Falconi M et al (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4):1083–1092PubMedCrossRefGoogle Scholar
  77. 77.
    Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523PubMedCrossRefGoogle Scholar
  78. 78.
    Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513PubMedCrossRefGoogle Scholar
  79. 79.
    Tanimoto A, Matsuki Y, Tomita T, Sasaguri T, Shimajiri S, Sasaguri Y (2004) Histidine decarboxylase expression in pancreatic endocrine cells and related tumors. Pathol Int 54(6):408–412PubMedCrossRefGoogle Scholar
  80. 80.
    Bordi C, Pilato FP, D'Adda T (1988) Comparative study of seven neuroendocrine markers in pancreatic endocrine tumours. Virchows Arch A Pathol Anat Histopathol 413(5):387–398PubMedCrossRefGoogle Scholar
  81. 81.
    Lloyd RV, Mervak T, Schmidt K, Warner TF, Wilson BS (1984) Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol 8(8):607–614PubMedCrossRefGoogle Scholar
  82. 82.
    Chejfec G, Falkmer S, Grimelius L et al (1987) Synaptophysin. A new marker for pancreatic neuroendocrine tumors. Am J Surg Pathol Apr 11(4):241–247CrossRefGoogle Scholar
  83. 83.
    Simpson S, Vinik AI, Marangos PJ, Lloyd RV (1984) Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase. Cancer 54(7):1364–1369PubMedCrossRefGoogle Scholar
  84. 84.
    Tomita T, Kimmel JR, Friesen SR, Doull V, Pollock HG (1985) Pancreatic polypeptide in islet cell tumors. Morphologic and functional correlations. Cancer 56(7):1649–1657PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Irvin M. Modlin
    • 1
    Email author
  • Steven F. Moss
    • 2
  • Bjorn I. Gustafsson
    • 3
    • 4
  • Ben Lawrence
    • 1
  • Simon Schimmack
    • 1
    • 5
  • Mark Kidd
    • 1
  1. 1.Gastrointestinal Pathobiology GroupYale University School of MedicineNew HavenUSA
  2. 2.Liver Research CenterBrown UniversityProvidenceUSA
  3. 3.Department of Gastroenterology, St Olavs HospitalNorwegian University of Science and TechnologyTrondheimNorway
  4. 4.Department of Cancer Research and Molecular MedicineNorwegian University of Science and TechnologyTrondheimNorway
  5. 5.Department of General, Visceral, and Transplantation Surgery, Heidelberg University HospitalHeidelbergGermany

Personalised recommendations